Home Cart Sign in  
Chemical Structure| 315183-21-2 Chemical Structure| 315183-21-2

Structure of PAC-1
CAS No.: 315183-21-2

Chemical Structure| 315183-21-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PAC-1 is a potent procaspase-3 activator with EC50 of 0.22 μM which activate procaspase-3 to caspase-3 and induces apoptotic death in cancer cells in culture and in mouse xenograft models.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PAC-1

CAS No. :315183-21-2
Formula : C23H28N4O2
M.W : 392.49
SMILES Code : O=C(N/N=C/C1=CC=CC(CC=C)=C1O)CN2CCN(CC3=CC=CC=C3)CC2
MDL No. :MFCD02051977
InChI Key :YQNRVGJCPCNMKT-LFVJCYFKSA-N
Pubchem ID :135421197

Safety of PAC-1

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H372-H410
Precautionary Statements:P501-P273-P260-P270-P264-P280-P391-P314-P337+P313-P305+P351+P338-P301+P312+P330
Class:9
UN#:3077
Packing Group:

Related Pathways of PAC-1

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SK-MEL-5 cells 25 μM 1 hour Determine the subcellular localization of 2h, showing that 2h localizes in the cytoplasm, similar to other fluorescent zinc chelators PMC2749958
MCF7 75 µM 24 h To study apoptosis and cell cycle arrest induced by PAC-1 PMC3877569
HeLa 100 µM 24 h To investigate whether PAC-1 induces DNA damage PMC3877569
EL4 10 μM 24 hours To evaluate the cell death effect of PAC-1 in combination with doxorubicin, results showed that PAC-1 significantly enhanced doxorubicin-induced cell death. PMC4999974
RAD51-EGFP_SW480 cells 0.1–100 μM 24 hours PAC-1 induced RAD51 nuclear foci formation, indicating DNA damage PMC6172261
HepG2 cells 30 μM 24 hours PAC-1 induced pH2AX, indicating DNA damage PMC6172261
HIF1α-EGFP_CHO cells 3 μM and 30 μM 3 hours PAC-1 significantly induced HIF1α nuclear translocation PMC6172261
K7M2 30 μM 48 hours To evaluate the cell death effect of PAC-1 in combination with doxorubicin, results showed that PAC-1 significantly enhanced doxorubicin-induced cell death. PMC4999974
U-937 (human lymphoma) 10.2 ± 0.3 μM 72 hours Evaluation of PAC-1 cytotoxicity on U-937 cells, IC50 value is 10.2 ± 0.3 μM. PMC4520234
Jurkat (human leukemia) 4.4 ± 0.6 μM 72 hours Evaluation of PAC-1 cytotoxicity on Jurkat cells, IC50 value is 4.4 ± 0.6 μM. PMC4520234
GL-1 (dog lymphoma) 3.0 ± 0.1 μM 72 hours Evaluation of PAC-1 cytotoxicity on GL-1 cells, IC50 value is 3.0 ± 0.1 μM. PMC4520234
OSW (dog lymphoma) 10.0 ± 0.8 μM 72 hours Evaluation of PAC-1 cytotoxicity on OSW cells, IC50 value is 10.0 ± 0.8 μM. PMC4520234
EL4 (mouse lymphoma) 6.5 ± 0.5 μM 72 hours Evaluation of PAC-1 cytotoxicity on EL4 cells, IC50 value is 6.5 ± 0.5 μM. PMC4520234
IOMM-Lee 2.3 µM 72 hours PAC-1 induces apoptosis, confirmed by Annexin V and PI staining, PARP-1 cleavage, and increased caspase-3/-7 activity. PMC8485451
SF6717 3.1 µM 72 hours PAC-1 induces apoptosis, confirmed by Annexin V and PI staining, PARP-1 cleavage, and increased caspase-3/-7 activity. PMC8485451
CH157-MN 2.3 µM 72 hours PAC-1 induces apoptosis, confirmed by Annexin V and PI staining, PARP-1 cleavage, and increased caspase-3/-7 activity. PMC8485451

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice osteosarcoma and lymphoma models Oral and intravenous 100 mg/kg administered on day 7 and day 14, lasting 2 weeks To evaluate the antitumor effect of PAC-1 in combination with doxorubicin, results showed that the combination significantly extended the survival of mice and reduced tumor burden. PMC4999974
Canine Canine meningioma model Oral 10 mg/kg Daily for 28 days PAC-1 + HU treatment did not significantly alter tumor volume, and [18F]C-SNAT4 tracer showed no significant changes in apoptosis within the tumor. PMC8485451

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02355535 Solid Tumor|Pancreatic Neuroen... More >>docrine Tumor|Neuroendocrine Tumors Less << PHASE1 COMPLETED 2020-05-18 University of Illinois at Chic... More >>ago, Chicago, Illinois, 60612, United States|Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, 21231, United States|Regions Hospital, Saint Paul, Minnesota, 55101, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.55mL

0.51mL

0.25mL

12.74mL

2.55mL

1.27mL

25.48mL

5.10mL

2.55mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories